{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:54:58Z","timestamp":1787846098448,"version":"build-2784847793"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clgc.2013.11.017","type":"journal-article","created":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T11:02:14Z","timestamp":1385895734000},"page":"e47-e49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Extensive Necrotizing Fasciitis Associated With Sunitinib Therapy"],"prefix":"10.1016","volume":"12","author":[{"given":"Jolanta","family":"Piszczek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Ruether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Urbanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.clgc.2013.11.017_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","article-title":"Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib","volume":"21","author":"Carrato Mena","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clgc.2013.11.017_bib2","series-title":"Sutent (sunitinib malate) [drug monograph]","year":"2013"},{"key":"10.1016\/j.clgc.2013.11.017_bib3","first-page":"557","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2013.11.017_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/511638","article-title":"Necrotizing soft-tissue infection: diagnosis and management","volume":"44","author":"Anaya","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clgc.2013.11.017_bib5","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2106\/00004623-200308000-00005","article-title":"Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality","volume":"85","author":"Wong","year":"2003","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.clgc.2013.11.017_bib6","series-title":"Principles and Practice of Infectious Diseases","first-page":"1172","article-title":"Cellulitis and subcutaneous tissue infections","author":"Schwartz","year":"2005"},{"key":"10.1016\/j.clgc.2013.11.017_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00000658-199505000-00013","article-title":"Determinants of mortality in necrotizing soft tissue infections","volume":"221","author":"McHenry","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.clgc.2013.11.017_bib8","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00268-007-9132-1","article-title":"Necrotizing soft tissue infections: APACHE II score, dissemination, and survival","volume":"31","author":"Yilmazlar","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.clgc.2013.11.017_bib9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2013.11.017_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1215\/15228517-2007-024","article-title":"Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma","volume":"9","author":"deBouard","year":"2007","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clgc.2013.11.017_bib11","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clgc.2013.11.017_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000073281","article-title":"Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors","volume":"33","author":"Kuenen","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.clgc.2013.11.017_bib13","first-page":"55","article-title":"Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer","volume":"9","author":"Gamboa","year":"2010","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clgc.2013.11.017_bib14","unstructured":"Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Sutent (sunitinib malate) Capsules: November 2012. Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm224050.htm. Accessed: May 1,\u00a02013."},{"key":"10.1016\/j.clgc.2013.11.017_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313002887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313002887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:22:51Z","timestamp":1761564171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767313002887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1558767313002887"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2013.11.017","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extensive Necrotizing Fasciitis Associated With Sunitinib Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2013.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}